Recent years have seen a rapid expansion in immune-based cancer treatments, most notably using antibodies that target immune checkpoint (IC) receptors PD-1 or the co-regulatory inhibitory cytotoxic T cell receptor CTLA-4, and their ligands PD-L1/2 and CD86 and CD80, respectively. Here, CD274 is linked to cancer.